- 米国企業
- HERON THERAPEUTICS, INC.
HERON THERAPEUTICS, INC.HRTX
| 2011年
12月31日 | 2012年
12月31日 | 2013年
12月31日 | 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 |
|---|
| Net loss | -12 | -23 | -55 | -76 | -98 | -173 | -197 | -179 | -205 | -227 | -221 | -182 |
|---|
| Stock-based compensation expense | 2 | 6 | 11 | 8 | 14 | 26 | 31 | 33 | 51 | 50 | 47 | 43 |
|---|
| Depreciation and amortization | - | - | - | - | - | - | 2 | 2 | 2 | 3 | 3 | 3 |
|---|
| Amortization of debt discount | 0 | 0 | 533,000 | 573,000 | 624,000 | 1 | 1 | 1 | 1 | 1 | 1 | - |
|---|
| Amortization of debt issuance costs | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
|---|
| Amortization of premium (accretion of discount) on short-term investments | - | - | - | - | - | - | 0 | 3 | 4 | -0 | -0 | 1 |
|---|
| Realized gain on available-for-sale investments | - | - | - | - | - | - | - | - | 8,000 | - | - | - |
|---|
| Asset Impairment Charges | - | - | - | 1 | - | - | - | 0 | 0 | 1 | 0 | 0 |
|---|
| Loss on disposal of property and equipment | - | - | - | -0 | 118,000 | -0 | -0 | -0 | -0 | - | -1 | -0 |
|---|
| Accounts receivable | 0 | - | - | - | - | 2 | 40 | 23 | -25 | 2 | -6 | 17 |
|---|
| Inventory | - | - | - | - | - | 5 | 5 | 29 | -14 | 17 | 6 | 6 |
|---|
| Prepaid expenses and other assets | 0 | -0 | 0 | 0 | 2 | 0 | -0 | 7 | 12 | -1 | 8 | -1 |
|---|
| Accounts payable | 0 | 1 | -0 | 1 | 751,000 | 4 | 12 | -2 | -14 | -2 | 3 | -1 |
|---|
| Increase Decrease In Clinical Liabilities | - | - | - | 2 | 1 | 8 | 14 | -4 | 10 | 15 | -26 | 1 |
|---|
| Accrued payroll and employee liabilities | - | - | - | 0 | 2 | 4 | 0 | 5 | 2 | -2 | 2 | -2 |
|---|
| Other accrued liabilities | - | - | - | 3 | 2 | 2 | 11 | 15 | 5 | -7 | -5 | 13 |
|---|
| Net cash used in operating activities | -8 | -17 | -41 | -60 | -78,526,000 | -134 | -170 | -192 | -125 | -185 | -203 | -147 |
|---|
| Purchases of short-term investments | - | - | - | - | - | - | - | - | 477 | 134 | 129 | 146 |
|---|
| Maturities and sales of short-term investments | - | - | - | - | - | - | 132 | 228 | 462 | 350 | 165 | 144 |
|---|
| Purchases of property and equipment | 1 | 1 | 2 | 1 | 1 | 3 | 3 | 9 | 7 | 7 | 3 | 2 |
|---|
| Proceeds from the sale of property and equipment | - | - | - | - | 241,000 | - | 0 | 0 | - | - | 0 | 0 |
|---|
| Net cash provided by (used in) investing activities | -1 | -1 | -2 | -1 | -56,960,000 | 15 | 8 | -279 | -22 | 209 | 33 | -3 |
|---|
| Net proceeds from sale of common stock | - | - | 58 | 59 | - | - | - | - | 162 | - | - | 75 |
|---|
| Proceeds from Convertible Debt | - | 3 | - | - | - | - | - | - | - | - | 149 | - |
|---|
| Proceeds from purchases under the Employee Stock Purchase Plan | 0 | 0 | 0 | 0 | 257,000 | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
|---|
| Proceeds From Payments For Stock Issued Under The Equity Incentive Plan | - | - | - | - | - | - | - | - | - | - | - | -2 |
|---|
| Net cash provided by financing activities | 24 | 54 | 61 | 62 | 138 | 57 | 294 | 358 | 186 | 9 | 156 | 75 |
|---|
| Net decrease in cash and cash equivalents | - | - | - | - | - | - | - | - | 40 | 33 | -15 | -75 |
|---|
| Interest paid | - | - | - | - | - | - | 3 | 1 | - | - | 1 | 2 |
|---|